Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
Achilles Therapeutics Announces Strategic Update
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics to Present at Upcoming Conferences
3 Stocks With 1,000% Upside Potential
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock
Achilles Therapeutics to Present at Upcoming Conferences
Achilles Therapeutics to Present at Upcoming Conferences
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)
Achilles Therapeutics to Present at Upcoming Scientific Congresses
Achilles Therapeutics to Present at Upcoming Investor Conferences
Achilles Therapeutics Announces Grant of US and European Patents
Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
U.S. IPO Weekly Recap: The IPO Market Slows With 6 IPOs In The Shortened Holiday Week
Achilles Therapeutics and Coursera Open for Trading Today
UK-based Achilles Therapeutics unveils US$175.5mln IPO at Nasdaq debut
Achilles Therapeutics Announces Pricing of Initial Public Offering
A.M. Best Affirms Credit Ratings of AXIS Specialty Limited and AXIS Capital Holdings Limited
A.M. Best Affirms Ratings of Markel Corporation and Its Subsidiaries
A.M. Best Removes From Under Review and Affirms Ratings of AXIS Capital Holdings Limited and Its Subsidiaries
A.M. Best Places the Ratings of AXIS Capital Holdings Limited and Its Subsidiaries under Review with Negative Implications
A.M. Best Affirms Ratings of AXIS Specialty Limited and AXIS Capital Holdings Limited
A.M. Best Ratings Upgrades Ratings of AXIS Capital Holdings Limited
A.M. Best Affirms Ratings of AXIS Capital Holdings Limited and Its Subsidiaries
A.M. Best Revises Outlook to Positive for AXIS Specialty Limited and Its Operating Affiliates